NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
Clinical Trials
12 trialsNCT06915766 2026-03-09
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT04360005 2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available
NCT01881334 2025-11-20
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Duke University
Available
NCT04008524 2025-08-06
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Available
NCT05738538 2025-06-04
Expanded Access to Ziftomenib
Kura Oncology, Inc.
Available
NCT03145545 2025-05-22
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Children's Hospital of Philadelphia
Available
NCT05593185 2024-12-09
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Sellas Life Sciences Group
Available
NCT00854841 2009-03-03
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Pusan National University Hospital
Available